According to the Trial of PARP Inhibition in Prostate Cancer (TOPARP)‐A and TOPARP‐B, the PARP inhibitors have achieved great progress in the treatment of mCRPC patients who carry HRR deficiency.32, 33. Here, PARP1 is linked to prostate carcinoma.